Tshepo Nkuna, CSIR Researcher
Globally, more than a million people have died due to Covid-19 and there is neither treatment nor vaccine approved as yet. The current recommended strategies for preventing the spread of Covid-19 have shown little success. However, like other viruses, the spike proteins (class 1 fusion) mediate infection and the virus requires a host to replicate and propagate. The CSIR has developed targeted nanomedicines incorporating therapeutics that inhibit cellular infection (prevention) and nucleoside analogs that disrupt the replication of the viral genome resulting in early sequence termination (treatment). We have successfully shown inhibition of cellular infections by a pseudovirus with class 1 fusion proteins in-vitro.